Publications

Explore our latest thinking in non-viral gene engineering, developments in our targeted CAR-T programs in oncology, and more. Read the latest publications, research, and presentations on our science, from cancer to rare genetic disease.

Scientific Publications

Cas-CLOVER is a novel high-fidelity nuclease for safe and robust generation of T<sub>SCM</sub>-enriched allogeneic CAR-T cells - profile

Cas-CLOVER is a novel high-fidelity nuclease for safe and robust generation of TSCM-enriched allogeneic CAR-T cells

Molecular Therapy - Nucleic Acids
June 29, 2022
Blair Madison, Deepak Patil, Maximilian Richter, Xianghong Li, Stacey Cranert, Xinxin Wang, Renata Martin, Haibin Xi, Yening Tan, Leslie Weiss, Karl Marquez, Julia Coronella, Devon J. Shedlock, Eric Ostertag

Scientific Presentations

Sustained Factor VIII Activity Following Single Dose of Non-Viral Integrating Gene Therapy - profile

Sustained Factor VIII Activity Following Single Dose of Non-Viral Integrating Gene Therapy

American Society of Hematology (ASH) ​64th Annual Meeting​ Oral Presentation, New Orleans, Louisiana
Brian Truong1*, Giang N. Nguyen, BS2*, Khal Hajj, PhD1*, Joseph Lucas, PhD1*, Johannes Schwerk, PhD1*, James Yen1*, Kevin Briseno1*, Michelle Burrascano1*, Daniel Smith1*, Johnnatan Tamayo1*, Fernando Lopez-Espinoza1*, Michael Bennett, PhD1*, Blair Madison, PhD1*, Denise E. Sabatino, PhD2 and Joshua Rychak1*; 1Poseida Therapeutics, San Diego, CA; 2The Raymond G. Perelman Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia, Philadelphia, PA
Development of an allogeneic CAR-T targeting MUC1-C (MUC1, cell surface associated, C-terminal) for epithelial derived tumors - profile

Development of an allogeneic CAR-T targeting MUC1-C (MUC1, cell surface associated, C-terminal) for epithelial derived tumors

European Society for Medical Oncology (ESMO) Immuno-Oncology 2022 Annual Congress Poster Presentation, Geneva, Switzerland
David Y. Oh,1 Jason T. Henry,2 Joaquina Baranda,3 Ecaterina E. Dumbrava,4 Ezra Cohen,5 Rajesh Belani,6 Jeff D. Eskew,6 Joanne McCaigue,6 Hamid Namini,6 Christopher E. Martin,6 Ann Murphy,6 Eric Ostertag,6 Julia Coronella,6 Devon J. Shedlock,6 Ildefonso Rodriguez-Rivera,7 1University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; 2Sarah Cannon Research Institute at HealthOne, Denver, CO; 3University of Kansas Cancer Center, Kansas City, KS; 4MD Anderson Cancer Center, Houston, TX; 5University of California San Diego, San Diego, CA; 6Poseida Therapeutics, Inc., San Diego, CA; 7NEXT Oncology, San Antonio, TX
Phase I Study to Assess the Safety and Efficacy of P-BCMA-ALLO1, a Fully Allogeneic CAR T Therapy, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM) - profile

Phase I Study to Assess the Safety and Efficacy of P-BCMA-ALLO1, a Fully Allogeneic CAR T Therapy, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

European Society for Medical Oncology (ESMO) Immuno-Oncology 2022 Annual Congress Poster Presentation, Geneva, Switzerland
Mehmet Kocoglu1, Adam Asch2, Aravind Ramakrishnan3, Carlos Bachier4, Thomas Martin III5, Tulio Rodriguez6, Katherine McArthur7, Joanne McCaigue7, Christopher E. Martin7, Maggie Zhang7, Hamid Namini7, Eric Ostertag7, Matthew A. Spear8, Ellen Christie7, Rajesh Belani7, Stacey Cranert7, Julia Coronella7, Devon J. Shedlock7, Caitlin Costello9, 1University of Maryland GreenebaumCancer Center, Baltimore, MD; 2Stephenson Cancer Center, Oklahoma University, Oklahoma City, OK; 3Sarah Cannon Transplant and Cellular Therapy Program at St. David’s South Austin Medical Center, Austin, TX; 4Sarah Cannon Transplant and Cellular Therapy Program at Methodist Hospital, San Antonio, TX; 5UCSF Medical Center at Parnassus, San Francisco, CA; 6Bone Marrow Transplantation, Advocate Lutheran General Hospital, Park Ridge, IL; 7Poseida Therapeutics, Inc., San Diego, CA; 8Denovo Biopharma, San Diego, CA; 9UCSD MooresCancer Center, La Jolla, CA
Phase 1 Study of P-MUC1C-ALLO1 Allogeneic CAR-T Cells in Patients With Epithelial-Derived Cancers - profile

Phase 1 Study of P-MUC1C-ALLO1 Allogeneic CAR-T Cells in Patients With Epithelial-Derived Cancers

Society for Immunotherapy of Cancer (SITC) Annual Meeting 2022 Trials in Progress Poster Presentation, Boston
Jason T. Henry,1 Ildefonso Ismael Rodriguez Rivera,2 Joaquina Baranda,3 Ecaterina E. Dumbrava,4 Ezra Cohen,5 Rajesh Belani,6 Jeff D. Eskew,6 Joanne McCaigue,6 Hamid Namini,6 Christopher E. Martin,6 Ann Murphy,6 Eric Ostertag,6 Julia Coronella,6  Devon J. Shedlock,6 David Y. Oh7 1Sarah Cannon Research Institute, Nashville, TN; 2NEXT Oncology, San Antonio, TX; 3University of Kansas Cancer Center, Kansas City, KS; 4MD Anderson Cancer Center, Houston, TX; 5University of California San Diego, San Diego, CA; 6Poseida Therapeutics, Inc., San Diego, CA; 7University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
Allogeneic T<sub>SCM</sub>-based TCR-T for Oncology and Beyond - profile

Allogeneic TSCM-based TCR-T for Oncology and Beyond

7th Annual CAR-TCR Summit 2022, Boston
Devon J. Shedlock, Chief Scientific Officer, Cell Therapy
Anti-c-kit CAR-T Cells Enable HSC Engraftment in a Humanized Model of Stem Cell Transplant Conditioning - profile

Anti-c-kit CAR-T Cells Enable HSC Engraftment in a Humanized Model of Stem Cell Transplant Conditioning

American Society of Gene and Cell Therapy Annual Meeting 2022 Poster Presentation, Washington, D.C.
Chao Yang, Luis Munoz, Caroline Stienne, Peng Fei Huang, Michelle Burrascano, Eric M. Ostertag, Devon J. Shedlock, Julian D. Down and Nina D. Timberlake
Phase 1 Study of P-PSMA-101 CAR-T Cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) - profile

Phase 1 Study of P-PSMA-101 CAR-T Cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

2022 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) Poster Presentation, San Francisco
Susan Slovin,1 Tanya Dorff,2 Gerald Falchook,3 Xiao Wei,4 Xin Gao,5 Rana R. McKay,6 David Oh,7 Andreas Wibmer,1 Matthew Spear,8 Joanne McCaigue,8 Devon J. Shedlock,8 Julia Coronella,8 Manjima Dhar,8 Hamid Namini,8 Chris Martin,8 Majid Ghodussi,8 Ann Murphy,8 Eric Ostertag8 | 1Memorial Sloan Kettering Cancer Center, New York, NY; 2City of Hope Comprehensive Cancer Center, Duarte, CA; 3Sarah Cannon Research Institute, Denver, CO; 4Dana-Farber Cancer Institute, Boston, MA; 5Massachusetts General Hospital, Boston, MA; 6University of California San Diego, La Jolla, CA; 7University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; 8Poseida Therapeutics, Inc., San Diego, CA
Phase 1 Study of P-PSMA-101 CAR-T Cells in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) - profile

Phase 1 Study of P-PSMA-101 CAR-T Cells in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

2022 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) Poster Presentation Slides, San Francisco
Susan Slovin, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY
VIDEO: Phase 1 Study of P-PSMA-101 CAR-T Cells in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) - profile

VIDEO: Phase 1 Study of P-PSMA-101 CAR-T Cells in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

2022 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) Poster Presentation Video File, San Francisco
Susan Slovin, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY
Clinical Trials of BCMA-Targeted CAR-T Cells Utilizing a Novel Non-Viral Transposon System - profile

Clinical Trials of BCMA-Targeted CAR-T Cells Utilizing a Novel Non-Viral Transposon System

American Society of Hematology (ASH) Annual Meeting 2021 Poster Presentation, Atlanta, Georgia
Caitlin Costello, MD, Ben A Derman, MD, Mehmet Hakan Kocoglu, MD, Abhinav Deol, Syed Abbas Ali, MD, Tara Gregory, MD, Bhagirathbhai Dholaria, MBBS, Jesus G Berdeja, MD, Adam D Cohen, MD, Krina K. Patel, MD, MSc, David S. Siegel, MD, PhD, Rajneesh Nath, MD, Katherine McArthur, Joanne McCaigue, M.S., Christopher E Martin, PhD, Majid Ghoddusi, PhD, DVM, Hamid Namini, Ph.D., Eric M. Ostertag, MD, PhD, Matthew A. Spear, MD, Rajesh Belani, MD and Nina Shah, MD
Correction of Severe Ornithine Transcarbamylase Deficiency in Growing Neonatal Murine Liver using Combined Adeno-Associated Virus and Nanoparticle Delivery of piggyBac<sup>®</sup> Transposon System - profile

Correction of Severe Ornithine Transcarbamylase Deficiency in Growing Neonatal Murine Liver using Combined Adeno-Associated Virus and Nanoparticle Delivery of piggyBac® Transposon System

14th International Congress of Inborn Errors of Metabolism (ICIEM 2021), Virtual
Bernard Kok, Xinggang Liu, David Ebeid, Xianghong Li, Ryan Weiss, Nairika Meshgin, Arturo Barcenas, Naha Parayath, Jivan Yewle, Brian Truong, Blair Madison, Bruce F. Scharschmidt, Julian D. Down, Devon J. Shedlock, Jack Rychak, Eric M. Ostertag and Jingjing Jiang
Memory Phenotype in Allogeneic Anti-BCMA CAR-T Cell Therapy (P-BCMA-ALLO1) Correlates with In Vivo Tumor Control - profile

Memory Phenotype in Allogeneic Anti-BCMA CAR-T Cell Therapy (P-BCMA-ALLO1) Correlates with In Vivo Tumor Control

Society for Immunotherapy of Cancer (SITC) Annual Meeting 2021 Poster Presentation, Virtual
Hubert Tseng, Yan Zhang, Stacey Cranert, Maximilian Richter, Karl Marquez, Jing Qiu, Benjamin Cho, Yening Tan, Min Tong, Christine Domingo, Leslie Weiss, Elvira Argus, Jessica Sparks, Eric Ostertag, Julia Coronella, Devon J. Shedlock
P-MUC1C-ALLO1: A Fully Allogeneic Stem Cell Memory T Cell (T<sub>SCM</sub>) CAR-T Therapy with Broad Potential in Solid Tumor - profile

P-MUC1C-ALLO1: A Fully Allogeneic Stem Cell Memory T Cell (TSCM) CAR-T Therapy with Broad Potential in Solid Tumor

Society for Immunotherapy of Cancer (SITC) Annual Meeting 2021 Poster Presentation, Virtual
Yan Zhang, Anna K. Kozlowska, Jacqueline Fritz, Yingying Zhao, Claudia Palomino La Torre, Stacey Cranert, Steven Wang, Rebecca Codde, Elvira Argus, Samad Ibitokou, Vanitra Richardson, Sumiti Jain, Maximilian Richter, Deepak Patil, Yening Tan, Min Tong, Lu Yao, Majid Ghoddusi, Eric M. Ostertag, Julia Coronella, Devon J. Shedlock
P-PSMA-101 is a High-Tscm Autologous CAR-T Targeting PSMA Producing Exceptionally Deep and Durable Responses in Castration-Resistant Metastatic Prostate Cancer (mCRPC) - profile

P-PSMA-101 is a High-Tscm Autologous CAR-T Targeting PSMA Producing Exceptionally Deep and Durable Responses in Castration-Resistant Metastatic Prostate Cancer (mCRPC)

6th Annual CAR-TCR Summit 2021, Virtual
Eric Ostertag, CEO
Developing piggyBac Systems “Off-the-Shelf” CAR-T Cells for Bone Marrow Transplant Conditioning - profile

Developing piggyBac Systems “Off-the-Shelf” CAR-T Cells for Bone Marrow Transplant Conditioning

6th Annual CAR-TCR Summit 2021, Virtual
Nina Timberlake, Associate Director Research, Gene Therapy
Advancing Nonviral Manufacturing for Multi-Product Allogeneic T-Cell Therapies - profile

Advancing Nonviral Manufacturing for Multi-Product Allogeneic T-Cell Therapies

6th Annual CAR-TCR Summit 2021, Virtual
Devon Shedlock, SVP Research & Development
Developing CAR-T Cells for Multiple Myeloma: From Autologous to Allogeneic - profile

Developing CAR-T Cells for Multiple Myeloma: From Autologous to Allogeneic

6th Annual CAR-TCR Summit 2021, Virtual
Matt Spear, CMO
Preclinical Evaluation of Combined AAV and Nanoparticle delivery of piggyBac® DNA Modification System for Durable Transgene Expression in the Growing Neonatal Murine Liver - profile

Preclinical Evaluation of Combined AAV and Nanoparticle delivery of piggyBac® DNA Modification System for Durable Transgene Expression in the Growing Neonatal Murine Liver

American Society of Gene and Cell Therapy Annual Meeting 2021 Oral Presentation, Virtual
Jingjing Jiang, M.D., Ph.D. Associate Director, Gene Therapy
Anti-c-kit CAR-T Cells Afford Effective Eradication of Human AML and Normal Hematopoietic Cells in a Preclinical Model of Safer, Non-Genotoxic Stem Cell Transplant Conditioning - profile

Anti-c-kit CAR-T Cells Afford Effective Eradication of Human AML and Normal Hematopoietic Cells in a Preclinical Model of Safer, Non-Genotoxic Stem Cell Transplant Conditioning

American Society of Gene and Cell Therapy Annual Meeting 2021 Poster Presentation, Virtual
Nina Timberlake, Ph.D., Associate Director, Gene Therapy
P-BCMA-ALLO1 — A Fully Allogeneic Stem Cell Memory T Cell (TSCM) CAR-T Therapy Targeting BCMA for the Treatment of Multiple Myeloma Shows Potent Anti-Tumor Activity - profile

P-BCMA-ALLO1 — A Fully Allogeneic Stem Cell Memory T Cell (TSCM) CAR-T Therapy Targeting BCMA for the Treatment of Multiple Myeloma Shows Potent Anti-Tumor Activity

American Society of Gene and Cell Therapy Annual Meeting 2021 Poster Presentation, Virtual
Maximilian Richter, Stacey A. Cranert, Deepak Patil, Yan Zhang, Yening Tan, Min Tong, Christine Domingo, Leslie Weiss, Karl Marquez, Jessica Sparks, Elvira Argus, Samad A. Ibitokou, Christopher E. Martin, Eric M. Ostertag, Sumiti Jain, Julia Coronella, Devon J. Shedlock
Efficacy and Safety of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) - profile

Efficacy and Safety of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM)

American Society of Hematology Annual Meeting (ASH) 2020 Oral Presentation, Virtual
C. Costello, A. D. Cohen, K. K. Patel, S. Abbas Ali, J. G. Berdeja, N. Shah, S. Ganguly, M. Kocoglu, M. Abedi, A. Deol, E. M. Ostertag, C. E. Martin, M. Ghoddusi, D. J. Shedlock, J. McCaigue, H. Namini, K. McArthur, S. Yalamanchili,M. A. Spear, T. K. Gregory
Cas-CLOVER™ Gene Editing for Allogeneic CAR-T Production - profile

Cas-CLOVER™ Gene Editing for Allogeneic CAR-T Production

Hanson Wade CRISPR 2.0 Conference
Blair Madison, Ph.D., Senior Director, Genetic Engineering
Manufacturing Matters in CAR-T: Small Changes Can Have a Big Impact - profile

Manufacturing Matters in CAR-T: Small Changes Can Have a Big Impact

CAR-TCR Digital Week Presentation
Eric Ostertag, M.D., PhD., Chairman & CEO
Manufacture of an Allogeneic CAR-T Stem Cell Memory Product Candidate for Multiple Myeloma, P-BCMA-ALLo1, Is Robust, Reproducible and Highly Scalable - profile

Manufacture of an Allogeneic CAR-T Stem Cell Memory Product Candidate for Multiple Myeloma, P-BCMA-ALLo1, Is Robust, Reproducible and Highly Scalable

American Society of Hematology Annual Meeting 2019 Poster Presentation, Orlando, FL
Stacey A. Cranert, Maximilian Richter, Min Tong, Leslie Weiss, Yening Tan, Xianghong Li, Eric M. Ostertag, Julia Coronella, Devon J. Shedlock
P-BCMA-ALLo1: A Non-Viral Allogeneic anti-BCMA CAR-T Therapy With Potent Anti-Tumor Function for the Treatment of Multiple Myeloma - profile

P-BCMA-ALLo1: A Non-Viral Allogeneic anti-BCMA CAR-T Therapy With Potent Anti-Tumor Function for the Treatment of Multiple Myeloma

Annual SITC 2019 Presentation by Maximilian Richter, Ph.D., National Harbor, MD
CAR-T Clinical Trials: New Directions in Biomarkers - profile

CAR-T Clinical Trials: New Directions in Biomarkers

Annual CAR-TCR Summit 2019 Presentation by Matthew A. Spear, MD., Boston, MA
Nonviral piggyBac® and Cas-CLOVER™ Genetic Engineering Technologies for Development of Stem Cell Memory (Tscm) CAR-Ts - profile

Nonviral piggyBac® and Cas-CLOVER™ Genetic Engineering Technologies for Development of Stem Cell Memory (Tscm) CAR-Ts

Annual CAR-TCR Summit 2019 Presentation by Devon J. Shedlock, PhD., Boston, MA
Update of the P-BCMA-101-001 Phase 1 Clinical Trial: A Novel Stem Cell Memory CAR-T for Relapsed/Refractory Multiple Myeloma - profile

Update of the P-BCMA-101-001 Phase 1 Clinical Trial: A Novel Stem Cell Memory CAR-T for Relapsed/Refractory Multiple Myeloma

Annual CAR-TCR Summit 2018 Presentation by Eric Ostertag, M.D. Ph.D., Boston, MA
P-MUC1C-101: A Stem Cell Memory CAR-T Therapy for Epithelial-Derived Solid Tumors - profile

P-MUC1C-101: A Stem Cell Memory CAR-T Therapy for Epithelial-Derived Solid Tumors

Annual CAR-TCR Summit 2018 Presentation by Devon Shedlock, Ph.D., Boston, MA
Manufacture of Allogeneic “Universal Donor” CAR-T Therapies Using piggyBac™ and Cas-CLOVER™ - profile

Manufacture of Allogeneic “Universal Donor” CAR-T Therapies Using piggyBac™ and Cas-CLOVER™

Annual CAR-TCR Summit 2018 Presentation by Burton Barnett, Ph.D., Boston, MA
PSMA-specific CAR-T Memory Stem Cell Therapy Eliminates Solid Tumors in Multiple Prostate Cancer Models - profile

PSMA-specific CAR-T Memory Stem Cell Therapy Eliminates Solid Tumors in Multiple Prostate Cancer Models

Annual CAR-TCR Summit 2018 Poster Presentation, Boston, MA
Jenessa B. Smith, Rebecca Codde, Yening Tan, Chris E. Martin, Burton E. Barnett, Srinivas Rengarajan, Eric M. Ostertag, Devon J. Shedlock
Non-Viral Engineered Human CAR-T Cells for Safe and Specific Stem Cell Transplant Conditioning - profile

Non-Viral Engineered Human CAR-T Cells for Safe and Specific Stem Cell Transplant Conditioning

American Society of Gene and Cell Therapy Annual Meeting 2018 Poster Presentation, Chicago, IL
Nina D. Timberlake, Natalie Chen, Claire S. Koechlein, Maximilian Richter, Armenuhi Avanesyan, Nicholas Cam, Xinxin Wang, Rebecca Codde, Yening Tan, Eric M. Ostertag, Devon J. Shedlock, Julian D. Down
Clinical Trial of P-BCMA-101 T stem cell memory (Tscm) CAR-T Cells in Relapsed/Refractory Multiple Myeloma - profile

Clinical Trial of P-BCMA-101 T stem cell memory (Tscm) CAR-T Cells in Relapsed/Refractory Multiple Myeloma

American Association of Cancer Research Annual Meeting 2018 Poster Presentation, Chicago, IL
K. Gregory1, J. G. Berdeja2, K. K. Patel3, S. Abbas Ali4, A. D. Cohen5, C. Costello6, E. M. Ostertag7, N. de Silva7, D. J. Shedlock7, C. Martin7, S. Rengarajan7, B. Barnett7, M. Resler7, M. A. Spear7, R. Z. Orlowski3 1Colorado Blood Cancer Inst., Denver, CO; 2Tennessee Oncology, Nashville, TN; 3MD Anderson Cancer Ctr., Houston, TX; 4Johns Hopkins Univ., Baltimore, MD; 5Abramson Cancer Ctr. Univ. of Pennsylvania, Philadelphia, PA; 6Moores Cancer Ctr., UC San Diego, San Diego, CA; 7Poseida Therapeutics, Inc., San Diego, CA, 92121
Cas-CLOVER™: A High-Fidelity Genome Editing System for Safe and Efficient Modification of Cells for Immunotherapy - profile

Cas-CLOVER™: A High-Fidelity Genome Editing System for Safe and Efficient Modification of Cells for Immunotherapy

2018 Precision CRISPR Congress Poster Presentation, Boston, MA
Xianghong Li, Xinxin Wang, Min Tong, Yening Tan, Julian D. Down, Devon J. Shedlock, Eric M. Ostertag